Gastric Cancer

Cancer Network spoke with Dr. Shaila Merchant about the difficulty in determining and linking the many disparities in gastric cancer and how genetic research can help.

Researchers found that adding andecaliximab to treatment for gastric cancer may benefit older patients.

As part of our coverage of the 2018 GI Cancers Symposium, we discussed the role of locoregional therapies for patients with metastatic esophageal and gastric cancers.

First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.

Undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis, according to data presented at the 2018 Gastrointestinal Cancers Symposium.

The FDA approved a biosimilar for trastuzumab, Ogivri, for the treatment of patients with HER2-positive breast and stomach cancer.

Do you know how many men and women are estimated to be diagnosed with gastric cancer this year? How about some of the known risk factors for this disease? Test your knowledge in our latest quiz.

The combination of olaparib plus paclitaxel failed to significantly improve overall survival compared with placebo plus paclitaxel in Asian patients with advanced gastric cancer, according to the phase III results of the GOLD study.

Adolescent obesity may be associated with an increased risk for non-cardia gastric cancer, according to the results from a cohort of almost 1.8 million men and women.

Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.

The FDA has granted accelerated approval to pembrolizumab (Keytruda) for the treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Updated results of the FLOT4-AIO trial confirmed the superiority of a docetaxel-based triplet regimen over the current standard of care in patients with resectable esophagogastric cancer.

Updated results from the KEYNOTE 059 phase II trial showed that pembrolizumab alone or in combination with chemotherapy has promising antitumor activity for patients with advanced gastric or gastroesophageal junction cancer.

A new study has shown that it may now be possible to predict survival outcomes and patients’ response to chemotherapy based on the molecular classification of four distinct subtypes of gastric cancer.

Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.

Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma.

Researchers from Johns Hopkins University report on a cascade of events that appears to correlate with early cancer recurrence and decreased overall survival.

Researchers in Seattle are now reporting success with a biopolymer synthetic scaffold loaded with cancer-fighting T cells and a mix of nutrients to potentially combat solid tumors.

Researchers at the Johns Hopkins University Bloomberg School of Public Health say they have found several gene variants which may predispose individuals to develop gall bladder cancer.

Overweight individuals in early adulthood who gained additional weight to become obese later in life are at an increased risk for esophageal and gastric cardia adenocarcinomas.

We spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

New data are suggesting that deciphering the genomic diversity and evolution of tumors may provide a basis for identifying new targets and designing improved personalized medicine strategies.

The Pancreatic Cancer Action Network is aiming to improve the lives of patients diagnosed with the third-leading cause of cancer-related death with a new precision drug trial.

If you’ve been in oncology long enough, you’ve likely seen the patient who presents with metastatic disease, gets first-line therapy, progresses, switches to second-line therapy, progresses again, and so on, with their cancer becoming increasingly more resistant to therapy.

Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.

Here we review the evidence supporting current approaches to resectable gastric cancer, including discussion of the optimal extent of surgery and lymphadenectomy, adjuvant chemotherapy, postoperative chemotherapy with chemoradiation, and perioperative chemotherapy.

Current methods of treatment still have a small impact on the survival of patients with localized disease. Improved understanding of the underlying mutations seen in gastric cancer might suggest alternative treatments and ways to better select patients.

Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.

Lymph node status after undergoing neoadjuvant chemotherapy and resection of esophagogastric cancer was the only independent predictor of survival.